Foundation for innovation
in Cardiometabolism and Nutrition

Research

  • What impact do endocrine disruptors have on metabolic liver disease? Support from the Crédit Mutuel Alliance Fédérale Foundation

    What impact do endocrine disruptors have on metabolic liver disease? Support from the Crédit Mutuel Alliance Fédérale Foundation

  • Clarivate ranking: 2 IHU ICAN researchers among the most cited in the world!

    Clarivate ranking: 2 IHU ICAN researchers among the most cited in the world!

  • Supporting research into cardiometabolism: a commitment to the health of tomorrow

    Supporting research into cardiometabolism: a commitment to the health of tomorrow

  • How can AI be used to stratify the risk of rare hereditary diseases?

    How can AI be used to stratify the risk of rare hereditary diseases?

  • Physical activity: an important treatment in cardiac rehabilitation

    Physical activity: an important treatment in cardiac rehabilitation

  • The ICONIC project: creation of the 1st atlas of cardiac and hepatic imaging in the general population, including people under the age of 40

    The ICONIC project: creation of the 1st atlas of cardiac and hepatic imaging in the general population, including people under the age of 40

  • Combating the cardiovascular risk of homozygous familial hypercholesterolemia: the IDEAL-HFHo project

    Combating the cardiovascular risk of homozygous familial hypercholesterolemia: the IDEAL-HFHo project

  • ICAN Scientific Day 2025 on Cardiometabolic Diseases

    ICAN Scientific Day 2025 on Cardiometabolic Diseases

  • What are the key takeaways from the symposium on cardiometabolic diseases at the Academy of Medicine?

    What are the key takeaways from the symposium on cardiometabolic diseases at the Academy of Medicine?

  • IHU ICAN’s flagship actions in 2024 to combat cardiometabolic diseases

    IHU ICAN’s flagship actions in 2024 to combat cardiometabolic diseases

ISO 9001 Certified

OUr Institutionnal Supporters

Our network